Ian Somaiya Recent News
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Alexion's Drug Trial Miss Doesn't Change Analysts' Long-Term Thesis
BMO Sets Outperform Rating, $26 Target On Ra Pharmaceuticals
A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results
Early Clinical Data Released For Celgene's CELMoD
Nomura's Takeaways From Meeting With Gilead Sciences' Management
UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data
UPDATE: Piper Jaffray Downgrades Rigel Pharmaceuticals on the Return of Fostamatinib
Mixed Response on Infinity Pharma as Shares Plunge Amid Phase I Data